Cover image not available

Costing statement : Pazopanib for the firstline treatment of advanced renal cell carcinoma

National Institute for Health and Clinical Excellence

Publication Data

Title Costing statement : Pazopanib for the firstline treatment of advanced renal cell carcinoma
Alternative Title Costing statement : TA215 Renal cell carcinoma (first line metastatic)
Author National Institute for Health and Clinical Excellence
Publisher National Institute for Health and Clinical Excellence
Publication date 2011
Publication location London
Language English

Descriptive Notes

"February 2011."

Topics

Renal cell carcinoma :: Chemotherapy :: Great Britain :: Cost effectiveness
Protein-tyrosine kinase :: Inhibitors
England

Catalogue Data

OBNB ID GBB586484
ISBN 10 n/a
ISBN 13 n/a
Type BibliographicResource, Book
Dewey Classification 616.99461061

ISBD

P1053 1 online resource (3 pages)
P1042 Includes bibliographical reference.

Buy a copy

OBNB doesn't sell books, but you may be able to find a copy at one of these websites:

Costing statement : Pazopanib for the firstline treatment of advanced renal cell carcinoma by National Institute for Health and Clinical Excellence. Published by National Institute for Health and Clinical Excellence in 2011. Publication and catalogue information, links to buy online and reader comments.